Clinical trials
PSMA clinical trials
Below are recruiting psma clinical trials, each written for real people, not researchers. We’re tracking 192 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07863986Recruiting
Studying response to lutetium therapy for advanced prostate cancer
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
KaunasAges 18 years+ - NCT07660211RecruitingPhase 1
Radioactive treatment for advanced prostate cancer
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06600802Recruiting
Lu-PSMA treatment for advanced prostate cancer
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
Clermont-FerrandAges 18 years+ - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
San Francisco, CaliforniaAges 18 years+ - NCT04886986RecruitingPhase 1
Testing a targeted radiation pill for advanced prostate cancer
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
Brooklyn, New YorkAges 18–99 - NCT05228106Recruiting
PSMA scan using 68Ga-PSMA-617 PET/CT
This study looks at a PSMA-targeted PET/CT scan using 68Ga-PSMA-617 for tumors that show a specific marker (PSMA). It’s meant to help confirm or evaluate suspected or known PSMA-expressing tumors in real-life clinical practice.
Sherbrooke, QuebecAges Any age - NCT07621692RecruitingPhase 1
New radioactive therapy for advanced prostate cancer
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
TaipeiAges 20 years+ - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT07208240RecruitingPhase 1/Phase 2
PSMA-targeted radiation before prostate removal for advanced cancer
This trial tests giving a radioactive drug (PSMA-targeted) before surgery for prostate cancer that has spread locally but not to other parts of the body. The goal is to see if it helps lower the risk of the cancer coming back.
Petah TikvaAges 18 years+ - NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT06923657Recruiting
PSMA PET/MRI for guiding biopsy after negative MRI
This study tests whether a special type of PET/MRI scan (PSMA PET/MRI) can help doctors find hidden prostate cancer in men who have a rising PSA but previous negative biopsies and a non-suspicious MRI. It aims to improve detection without skipping needed treatment.
Fuzhou, FujianAges 30–85 - NCT06835244Enrolling by invitation
Study of PSMA PET/CT scans for non-prostate cancers
This study looks at how well a special scan (PSMA PET/CT) works for people with cancers other than prostate cancer. If your doctor already scheduled this scan for your care, you may be able to help researchers learn more about its accuracy.
BolognaAges 18 years+ - NCT06059469RecruitingPhase 2
PSMA scan for advanced triple-negative breast cancer
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
BrusselsAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT05919329RecruitingPhase 4
PSMA scan changes after starting hormone therapy for prostate cancer
This study looks at how a prostate-specific scan marker (PSMA) changes after you start or continue hormone therapy. It may help doctors better understand who responds and how quickly prostate cancer biology shifts during treatment.
Portland, OregonAges 18 years+ - NCT04987086Recruiting
68Ga PSMA PET-CT for kidney cancer spread
This study checks whether a special PET-CT scan using 68Ga PSMA can better find where renal cell carcinoma has spread. It may help doctors plan the right next steps by confirming suspected metastases on CT.
Lanzhou, GansuAges 18–90 - NCT04402151RecruitingPhase 2
PSMA scan–guided targeted radiation for higher-risk prostate cancer
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
New York, New YorkAges 21–90 - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06167629Recruiting
PSMA PET scan study for prostate cancer
This study uses a special type of PET scan called PSMA PET to better understand and track prostate cancer. The scan helps doctors see where the cancer is in the body and if treatment is working.
MilanAges 18 years+ - NCT06220188RecruitingPhase 2
PSMA therapy for prostate cancer that has come back
This trial tests a targeted radiation therapy (PSMA-RLT) for men whose prostate cancer has returned after initial treatment, shown only by rising PSA levels. It aims to control the cancer without using hormone therapy.
ViennaAges 18–80 - NCT06259123RecruitingPhase 2
PSMA Radiotherapy Before Prostate Cancer Surgery
This trial tests a radioactive drug (PSMA-RLT) given before surgery for prostate cancer that has spread to a few spots. It aims to see if this treatment can stop the cancer from growing further.
ViennaAges 18–75 - NCT06320223Recruiting
PSMA PET scan registry for prostate cancer outcomes
This registry collects information from people with prostate cancer who have had a PSMA PET scan. Researchers want to learn how well this scan predicts outcomes over at least 3 years, which may help improve future care.
EssenAges 18 years+ - NCT06494696Recruiting
PSMA PET/MRI with MRI for prostate cancer risk
This study tests whether a special scan (PSMA PET/MRI) combined with a standard MRI can better detect prostate cancer. It is for men who have not had a biopsy yet and are suspected of having prostate cancer.
Taoyuan CityAges 40–85
Hear when a new PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma?
- Yes. Clin2 currently lists 192 recruiting psma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.